Lab Space Is Sending Two Very Different Signals
Lab space has one of the most unusual stories in real estate right now. The buildings are under pressure, but the companies that use them are starting to look healthier.
That split matters. Lab and R&D vacancy has reached a record high, and asking rents are down from last year. On the surface, that looks like a weak real estate story.
But the tenant side is not as weak as the property side. Venture funding is improving, and biotech hiring is also getting stronger. That means the demand base may be healing before the space market does.
Why This Is Happening
Lab buildings are not easy to fill. They are built for a special use, with costly systems, heavy power needs, and space made for science work. When demand slows, these buildings cannot always switch to another use as fast as a normal office or warehouse.
A lot of new lab space was planned when biotech money was easier to raise. Then funding slowed, and many firms cut costs. That left more space open just as new buildings reached the market.
Now the picture is starting to change. Biotech firms are hiring again, and funding is getting better. But real estate often takes time to heal. Empty space does not vanish right away just because tenant demand starts to improve.
What Many People Miss
The key story is the gap between the tenant market and the building market. Biotech can be getting healthier while lab vacancy is still high. Both can be true at the same time.
This is common in real estate. A sector can start to recover before landlords feel it in rents. Tenants may hire first, raise money first, and lease space later.
That is why investors need to watch both sides. Vacancy tells us what is happening to buildings today. Funding and hiring tell us what may happen to demand next.
Washington Is Betting More Than the Company Is Worth
Here's a number that shouldn't be possible.
On May 21, 2026, a federal board voted unanimously to lend roughly $3 billion to one American mining company. That loan is bigger than the company's entire market cap.
Think about what that says. The people who spent months inside this deal, with access to every drill report and every projection, decided this company deserves more capital than the market thinks the whole business is worth.
One of those valuations is wrong. The papers get signed in the second half of this year. After that, the market does the correcting.
What This Means For Buyers
Lab space may stay hard for owners in the near term. High vacancy gives tenants more choice, and lower rents can hurt building income. Owners with empty space may need to wait longer, offer better terms, or spend more to attract the right users.
Still, this is not a dead sector. If biotech keeps adding jobs and raising money, stronger lab markets may begin to fill again. The best buildings will likely be in places with deep talent, strong research hubs, and firms that need real lab space close by.
The winners may not be every lab building. They may be the best lab buildings in the best science markets.
By the Numbers
CBRE’s Q2 2026 data showed lab/R&D vacancy at 23.8%, a record high. Asking rents were down 8.1% from a year ago. At the same time, CBRE noted that venture funding and biotech hiring were both getting stronger, which shows a clear gap between weak space data and a better tenant outlook.
Bottom Line
Lab space is not giving a simple signal.
The real estate side is still under stress, but the tenant side is starting to improve.
That gap may create pain for weak owners and better entry points for patient buyers.
